TITLE:
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy

CONDITION:
Pain

INTERVENTION:
mexiletine

SUMMARY:

      OBJECTIVES:

      I. Assess the efficacy and toxicity of mexiletine in the management of paresthesias and pain
      in patients with diabetic neuropathy.
    

DETAILED DESCRIPTION:

      PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by
      participating institution.

      The first group receives oral mexiletine 3 times a day for 6 weeks. The dose is increased
      after the first week if there are no side effects.

      The second group receives a placebo. Patients cross to the alternate treatment after a
      1-week washout.
    

ELIGIBILITY:
Gender: All
Age: 21 Years to 60 Years
Criteria:

        Patients with painful diabetic neuropathy
      
